iStock 1217908833

Vabysmo® (faricimab)

Vabysmo® (faricimab) is approved to treat people with wet age-related macular degeneration (AMD) who have previously responded to at least 2 injections of an endothelial growth factor (VEGF) inhibitor into the eye. In people with wet AMD, Vabysmo is first given in 4 monthly injections. Based on outcomes, people will then receive their following Vabysmo injections every 2, 3, or 4 months. The current standard of care for wet AMD requires injections every 1 to 2 months . . .

Published in on May 9, 2022.